ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1232

Patient Reported Impact of Psoriatic Arthritis and Desired Treatment Outcomes

Elizabeth Luce1, Beth schneider2 and Dianna cronin2, 1MyHealthTeam, San Francisco, CA, 2MyHealthTeams, San Francisco, CA

Meeting: ACR Convergence 2024

Keywords: Biologicals, Psoriatic arthritis, quality of life

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 17, 2024

Title: Patient Outcomes, Preferences, & Attitudes Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: People living with psoriatic arthritis often struggle with the physical and mental health toll. Understanding the holistic impact of psoriatic arthritis is crucial to treating patients and enabling them to live more fulfilling lives. Purpose was to understand the impact of psoriatic arthritis (PsA) and desired treatment outcomes.

Methods: In August 2023, an email invitation to a 34-question online survey was sent to US members of MyPsoriasisTeam.

Results: In total, 265 respondents with PsA were included in the study. These respondents reported that PsA has a negative impact on overall quality of life (89%) and interferes with social life (74%). The physical toll manifested in difficulty exercising (83%) and challenges getting around (80%). The emotional toll of psoriatic arthritis was evident with 78% feeling depressed. Top symptoms include joint pain (92%), morning stiffness (90%), stiff joints (89%), and fatigue (89%).  Many continue to experience psoriasis related symptoms such as itching (70%) and red patches (57%). Top three treatment goals were consistent with symptom prevalence, including reducing joint pain (68%), joint stiffness (65%), and lessening fatigue (50%).  The majority (88%) are currently on some type of treatment for PsA, including biologics (48%) or oral steroids (36%).  Despite the fact that the large majority of respondents on biologics have benefited from their respective biologic treatment (87%), there remain obstacles to getting on a biologic among non-users that would need to be overcome, including concerns about side effects (56%), impact on immune system (53%), and long-term safety (49%).  The research also found that 41% of the respondents who indicated they only have psoriasis (n = 98) were showing signs of potential progression to psoriatic arthritis and may be underdiagnosed. Yet only 39% of psoriasis patients have discussed potential for progression with their dermatologist or other HCP.

Conclusion: Understanding the quality-of-life impact of psoriatic arthritis along with desired outcomes can help rheumatologists develop the most effective approach to treating patients. This includes listening to patient concerns about getting on specific treatments, helping them weigh the concerns against benefits and educating them on treatments to slow progression.

Supporting image 1

Impact of PsA on Quality of Life

Supporting image 2

Top PsA Treatment Goals From the Patient’s Perspective

Supporting image 3

Patient Reported Benefits of Biologics on PsA Symptoms


Disclosures: E. Luce: None; B. schneider: None; D. cronin: None.

To cite this abstract in AMA style:

Luce E, schneider B, cronin D. Patient Reported Impact of Psoriatic Arthritis and Desired Treatment Outcomes [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/patient-reported-impact-of-psoriatic-arthritis-and-desired-treatment-outcomes/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/patient-reported-impact-of-psoriatic-arthritis-and-desired-treatment-outcomes/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology